The FDA has recently began investigation of the possible association between the use of SINGULAIR and suicidality (suicidal thinking and behavior) and suicide. SINGULAIR is prescribed for asthma. The FDA advises patients not to stop taking SINGULAIR, but to talk to their doctor if they have questions.
The FDA has also advised healthcare professionals to carefully monitor patients taking SINGULAIR for changes in behavior and mood. Complete evaluation of the drug may take up to 9 months. Once the review is complete the FDA will communicate its recommendations to the public.
SINGULAIR is a leukotriene receptor antagonist. Several other drugs including CYMBALTA have been linked to suicidality and suicide. Help us keep America safe by telling your family and friends about the FDA’s concerns